, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Combination therapy in pulmonary arterial hypertension.

Pugh ME, Hemnes AR, Robbins IM
Clin Chest Med. 2013 34 (4): 841-55

PMID: 24267308 · DOI:10.1016/j.ccm.2013.08.007

Despite major advances in understanding the mechanisms of disease and development of specific drug therapy, pulmonary arterial hypertension (PAH) remains a progressive, fatal disease. At present there are 3 classes of drug therapy for PAH: prostaglandins, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. To maximize therapeutic benefit, and according to national and international guidelines, many patients are treated with combinations of these medications. This review presents a detailed account of the published data on the use of combination therapy in PAH. There are few randomized, placebo-controlled trial data to strongly support efficacy of most combination therapy, particularly oral combination therapy.

Copyright © 2013 Elsevier Inc. All rights reserved.

MeSH Terms (8)

Drug Therapy, Combination Endothelin Receptor Antagonists Epoprostenol Familial Primary Pulmonary Hypertension Humans Hypertension, Pulmonary Phosphodiesterase 5 Inhibitors Prostaglandins

Connections (1)

This publication is referenced by other Labnodes entities: